{
    "clinical_study": {
        "@rank": "37007", 
        "acronym": "rituximab", 
        "arm_group": [
            {
                "arm_group_label": "CT-P10", 
                "arm_group_type": "Experimental", 
                "description": "rituximab, CT-P10(experimental drug), 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion"
            }, 
            {
                "arm_group_label": "Rituxan", 
                "arm_group_type": "Active Comparator", 
                "description": "1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion"
            }, 
            {
                "arm_group_label": "MabThera", 
                "arm_group_type": "Active Comparator", 
                "description": "1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase 3 Study to Compare the Pharmacokinetics, Efficacy and Safety between CT-P10,\n      Rituxan and MabThera in Patients with Rheumatoid Arthritis."
        }, 
        "brief_title": "PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patient is male or female between 18 and 75 years old, inclusive.\n\n          2. Patient has a diagnosis of RA according to the revised 1987 ACR classification\n             criteria (Arnett et al 1988) for at least 6 months prior to randomization.\n\n          3. Patient has active disease as defined by the presence of 6 or more swollen joints (of\n             66 assessed) and 6 or more tender joints (of 68 assessed), and serum CRP \u22651.5 mg/dL\n             (\u226515 mg/L) or an ESR \u226528 mm/hour.\n\n          4. Patient has experienced an inadequate response to previous or current treatment with\n             the anti-TNF agents infliximab\n\n          5. Patient has a proper discontinuation period after treatment with interleukin-1\n             receptor (IL-1R) antagonist, interleukin-6 receptor (IL-6R) antibody, or abatacept.\n\n        Exclusion Criteria:\n\n          1. Patient has taken more than 2 biologic agents.\n\n          2. Patient has previously been administered Rituximab or participated in a Rituximab\n             biosimilar study.\n\n          3. Patient has allergies or hypersensitivity to murine, chimeric, human, or humanized\n             proteins.\n\n          4. Patient has current or past history of chronic infection with hepatitis B, hepatitis\n             C, or infection with human immunodeficiency virus (HIV)-1 or -2 or who has a positive\n             result to the screening test for these infections.\n\n          5. Patient has an infection requiring oral antibiotics 2 weeks before randomization,\n             parenteral injection of antibiotics 4 weeks before randomization, other serious\n             infection 6 months before randomization, a history of recurrent herpes zoster or\n             other chronic or recurrent infection 6 weeks before randomization."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02149121", 
            "org_study_id": "CT-P10 3.2", 
            "secondary_id": "2013-004555-21"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Rituxan", 
                    "MabThera"
                ], 
                "description": "1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion", 
                "intervention_name": "CT-P10", 
                "intervention_type": "Biological", 
                "other_name": [
                    "MabThera", 
                    "Rituxan"
                ]
            }, 
            {
                "arm_group_label": [
                    "CT-P10", 
                    "MabThera"
                ], 
                "description": "1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion", 
                "intervention_name": "Rituxan", 
                "intervention_type": "Drug", 
                "other_name": "rituximab"
            }, 
            {
                "arm_group_label": [
                    "CT-P10", 
                    "Rituxan"
                ], 
                "description": "1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion", 
                "intervention_name": "MabThera", 
                "intervention_type": "Drug", 
                "other_name": "rituximab"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Rituximab"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 28, 2014", 
        "link": {
            "description": "Company Homepage", 
            "url": "http://www.celltrion.com/"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Incheon", 
                    "country": "Korea, Republic of", 
                    "zip": "406840"
                }, 
                "name": "CELLTRION,Inc."
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Compare the Pharmacokinetics, Efficacy and Safety Between CT-P10, Rituxan and MabThera in Patients With Rheumatoid Arthritis", 
        "overall_contact": {
            "email": "SunYoung.Yu@celltrion.com", 
            "last_name": "SunYoung Yu", 
            "phone": "82 32 850 6559"
        }, 
        "overall_contact_backup": {
            "email": "MinJi.Kim2@celltrion.com", 
            "last_name": "MinJi Kim", 
            "phone": "82 32 850 6591"
        }, 
        "overall_official": {
            "affiliation": "Hanyang University", 
            "last_name": "DaeHyun Yoo, M.D., Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Austria: Austrian Medicines and Medical Devices Agency", 
                "Germany: Paul-Ehrlich-Institut", 
                "Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines", 
                "Latvia: State Agency of Medicines", 
                "Portugal: INFARMED, National Authority of Medicines and Health Products, IP", 
                "Slovak Republic: Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "AUC0 last: area under the serum concentration-time curve covering both infusions, time to the last measurable concentration\nAUC0-\u221e: area under the serum concentration-time curve covering both infusion, time zero to infinity\nCmax: maximum concentration after the second infusion", 
            "measure": "Pharmacokinetics", 
            "safety_issue": "No", 
            "time_frame": "over the first 24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02149121"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The change from Baseline in disease activity measured by DAS28 (CRP) at Week 24\nDAS28, Hybrid ACR, Joint damage", 
            "measure": "Efficacy parameter", 
            "safety_issue": "No", 
            "time_frame": "at Week 24"
        }, 
        "source": "Celltrion", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Celltrion", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}